Five companies disclosed new capital raises to the SEC in the last 72 hours, according to Form D filings reviewed for this report. The range is wide: a six-month-old AI research lab founded by an ex-OpenAI VP just sold $432M of a $635M offering, a 15-year-old battery materials company closed $300M to scale U.S. manufacturing, and three biotech and genomics companies raised between $6M and $70M to push clinical and commercial programs forward. Together, the five filings disclose more than $840M in fresh capital. Here is who raised, how much, and why it matters.
| Company | Amount Raised | Round | Key Investors | Date | Founders | Industry | Headquarters |
|---|---|---|---|---|---|---|---|
| Core Automation | $432M | Growth Financing | Nvidia, Spark Capital, Accel | Jul 30, 2026 | Jerry Tworek | Artificial Intelligence | San Francisco, CA |
| Sila Nanotechnologies | $300M | Growth Round | Atreides Management, Sutter Hill Ventures | Jul 31, 2026 | Gene Berdichevsky | Battery Materials | Alameda, CA |
| Ratio Therapeutics | $70M | Series C | Duquesne Family Office, Bristol Myers Squibb, Catalio Capital | Jul 31, 2026 | Jack Hoppin | Radiopharmaceuticals | Boston, MA |
| NextPoint Therapeutics | $33.7M | Growth Financing | Undisclosed | Jul 30, 2026 | Ivan Cheung | Immuno-Oncology | Cambridge, MA |
| Genomenon | $6M | Growth Financing | Undisclosed | Jul 30, 2026 | Mark Kiel | Genomic AI | Ann Arbor, MI |
Founded in January 2026 by ex-OpenAI VP of Research Jerry Tworek alongside former Google Brain/Gemini pretraining lead Rohan Anil and ex-OpenAI Chief People Officer Julia Villagra, Core Automation is building what it calls "the world's most automated AI lab" — betting that continual-learning architectures, not bigger transformers, are the next unlock for frontier AI. Six months after launch, the 16-person team has already sold $432M of a $635M SEC offering, with Nvidia, Spark Capital and Accel among its earliest backers.
Best For: Investors and researchers tracking the post-transformer AI race, and enterprises anticipating a shift toward small teams operating with highly capable, continuously learning agents.
No active roles listed on LinkedIn at this time — check the Core Automation jobs page for updates.
Sila just closed $300M to scale U.S. production of its silicon-carbon (Si/C) anode technology, Titan Silicon, at its Moses Lake, Washington plant. The round, co-led by Atreides Management and Sutter Hill Ventures with participation from 8VC, Bessemer Venture Partners, Matrix Partners and T. Rowe Price, pushes Sila's total funding past $1.3B and underlines investor appetite for domestic battery-materials manufacturing as EVs, AI data centers, drones and robotics all compete for next-gen battery capacity.
Best For: Automakers, consumer electronics OEMs and battery manufacturers looking for a drop-in silicon anode replacement that boosts energy density without re-engineering existing lithium-ion production lines.
Ratio closed a $70M Series C — with participation from Duquesne Family Office, Bristol Myers Squibb, Catalio Capital Management, Eli Lilly and Wasatch Group — to advance its lead radiotherapeutic, [Ac-225]RTX-2358, through the ATLAS study in advanced sarcomas and move a next-generation candidate into the clinic. The round brings Ratio's total raised past $240M as the radiopharmaceutical field enters a phase of clinical execution.
Best For: Oncology-focused biopharma partners and investors seeking exposure to targeted alpha-particle radiotherapeutics built on a proprietary chelation and targeting platform.
NextPoint's SEC filing shows $33.7M sold toward a $48.7M raise as the Cambridge biotech, led by CEO Ivan Cheung and CSO Tatiana Novobrantseva, advances its pipeline against the novel B7-H7/HHLA2 checkpoint — a pathway aimed at patients who don't respond to standard PD-1/L1 inhibitors. The company's lead antibody-drug conjugate candidate, NPX372, recently entered the clinic. The SEC filing does not disclose the participating investors.
Best For: Immuno-oncology investors looking for a differentiated checkpoint target and pharma partners seeking early access to a first-in-class B7-H7-directed pipeline.
No active roles listed on LinkedIn at this time — check the NextPoint Therapeutics jobs page for updates.
Genomenon, an Ann Arbor-based AI-driven genomic evidence company led by CEO Mike Klein and founder/CSO Mark Kiel, filed to raise $10M in growth capital, having already sold $6M. Its Mastermind platform mines over 39 million biomedical papers to surface real-world evidence used by 250+ diagnostic labs and 75 biopharma programs — recently helping expand FDA drug labels for Retevmo and Galafold. The SEC filing does not disclose the participating investors.
Best For: Diagnostic labs, biopharma clinical trial teams and rare-disease researchers who need regulatory-grade genomic evidence buried in the scientific literature, not just databases.
Choosing the right company
Three of this week's five raises — Core Automation, Sila Nanotechnologies and Ratio Therapeutics — are growth-stage companies with $70M+ rounds and clear commercial traction, while NextPoint Therapeutics and Genomenon are smaller, earlier-stage raises tied to specific clinical or product milestones. For job seekers, Sila and Ratio currently have the most open roles and salary transparency. For investors, Core Automation's six-month trajectory from founding to a $432M raise is the outlier worth watching most closely, while Sila's $300M round reflects steadier, capital-intensive scale-up economics in battery manufacturing.